Abstract:Glioma is the most common primary malignant tumor of the central nervous system. Despite traditional treatments such as surgical resection, combined postoperative chemotherapy, and radiotherapy, it remains challenging to significantly improve the long-term survival rate of patients. This is primarily due to the incomplete surgical removal of the tumor and its resistance to radiotherapy. Boron neutron capture therapy (BNCT) is a radiotherapy that can selectively kill tumor cells. Current research has demonstrated that BNCT offers effective local disease control for gliomas and head and neck tumors. However, the existing boron-containing drugs are still unsatisfactory due to their low boron content and poor targeting ability. The synergistic treatment has provided new ideas for the development of BNCT, and the emergence of nanosystems offers the possibility of prolonged retention and pinpoint delivery of boron drugs in the tumor cites. The unique tumor microenvironment(TME) of gliomas, characterized by the blood brain barrier (BBB), oxidative stress, hypoxia and angiogenesis, renders conventional treatments ineffective and poor prognosis. Therefore, to combine the TME regulation and BNCT therapy, we prepared a stable nanosystem in this study. It is a borane-contained cationic liposome modified with cRGD peptide which enhances the tumor-targeting ability. And the enzymes Lactate oxidase(LOX) and Catalase(CAT) are absorbed on the surface of the nanosystem which reduce the concentration of lactic acid through a cascade reaction to generate O2 and decrease the protein expression level of HIF-1α. This nanosystem exhibited a more potent anti-tumor effect both in vitro and in vivo. Also it reduced tumor stemness in vivo, which improves the prognosis. Therefore, the novel nanosystem combined microenvironment regulation therapy and BNCT shows the great potential application in anti-tumor treatment.

Intracranial C6 Gliomas Suppression by Stereotactic Injection of BCNU-loaded Nanoparticles Targeting for C6 Glioma Cells

Interpreting the Therapeutic Efficiency of Multifunctional Hybrid Nanostructure Against Glioblastoma

BCNU/PLGA Microspheres: a Promising Strategy for the Treatment of Gliomas in Mice.

Catalytic Modulation of the Tumor Microenvironment Using Cascade Enzymes for Synergistic Boron Neutron Capture Therapy in the Treatment of Gliomas

Evaluation of a Tumor-Targeting Oligosaccharide Nanosystem in BNCT on an Orthotopic Hepatocellular Carcinoma Model.

Cationic core-shell nanoparticles with carmustine contained within O⁶-benzylguanine shell for glioma therapy.

Peptide-functionalized gold nanoparticles for boron neutron capture therapy with the potential to use in Glioblastoma treatment

Tumor Eradication by Boron Neutron Capture Therapy with 10B‐enriched Hexagonal Boron Nitride Nanoparticles Grafted with Poly(glycerol)

Targeted Delivery of Chemo-Sonodynamic Therapy via Brain Targeting, Glutathione-Consumable Polymeric Nanoparticles for Effective Brain Cancer Treatment

Intravenous delivery of camptothecin-loaded PLGA nanoparticles for the treatment of intracranial glioma

Betulinic acid self-assembled nanoparticles for effective treatment of glioblastoma

Targeted Delivery of DNA Topoisomerase Inhibitor SN38 to Intracranial Tumors of Glioblastoma Using Sub‐5 Ultrafine Iron Oxide Nanoparticles

Dual-targeted TfRA4-DNA1-Ag@AuNPs: An innovative radiosensitizer for enhancing radiotherapy in glioblastoma multiforme

Self-protecting core-shell magnetic nanoparticles for targeted, traceable, long half-life delivery of BCNU to gliomas

Novel multi-drugs incorporating hybrid-structured nanofibers enhance alkylating agent activity in malignant gliomas

Enhancing Glioblastoma-Specific Penetration by Functionalization of Nanoparticles with an Iron-Mimic Peptide Targeting Transferrin/Transferrin Receptor Complex

Engineering Novel Targeted Boron-10-Enriched Theranostic Nanomedicine to Combat against Murine Brain Tumors via MR Imaging-Guided Boron Neutron Capture Therapy

Transferrin-modified Doxorubicin-loaded biodegradable nanoparticles exhibit enhanced efficacy in treating brain glioma-bearing rats.

Development and in vitro evaluation of carmustine delivery platform: A hypoxia-sensitive anti-drug resistant nanomicelle with BBB penetrating ability

Therapeutic nucleus-access BNCT drug combined CD47-targeting gene editing in glioblastoma

iRGD-mediated core-shell nanoparticles loading carmustine and O6-benzylguanine for glioma therapy